Randomized crossover comparison of two teriparatide self-injection regimens for primary osteoporosis: Interim report (end of 52-week treatment) of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06).

Soen S, Uemura Y, Tanaka S, Takeuchi Y, Endo N, Takada J, Ikeda S, Iwamoto J, Okimoto N, Tanaka S

Journal of bone and mineral metabolism18 Feb 2025Cited by 2 (Europe PMC)

PMID39966121PMCIDPMC12089251DOI10.1007/s00774-025-01586-yPepBankPUB-39966121

Summary

IntroductionPatient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.Materials and methodsQuestionnaires evaluated overall satisfaction, satisfaction with treatment effectiveness, satisfaction with utility of the self-injection device, and preference for a particular injection regimen after crossover. Quality of life (QOL), visual analogue scale pain scores, and bone mineral density (BMD) were also analyzed. Safety was evaluated based on the incidence and severity of adverse events (AEs).ResultsThe 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively. After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks. Significantly higher persistence was observed in the 1/D-TPTD to 2/W-TPTD group (p = 0.032). No significant between-group differences in overall satisfaction scores or satisfaction with treatment were observed. Satisfaction with the utility of the injection device was significantly higher with the 2/W-TPTD regimen (p < 0.05); this regimen was preferred by 69.4% of patients after crossover (p < 0.001). A significant increase in BMD from baseline was observed at the lumbar vertebrae in both groups and at the hip area in the 1/D-TPTD to 2/W-TPTD group at 52 weeks (p < 0.05). Significant improvement in the QOL score was observed in both groups (p < 0.05). No serious AEs were reported.ConclusionContinuation of this study will further clarify patient satisfaction, treatment effects, and tolerability.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with osteoporosis, quality-of-life scores improved significantly in both teriparatide sequence groups.
In plain wordsIn patients with osteoporosis, quality-of-life scores improved in both teriparatide sequence groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseQuality of life
Study
n = 358
Outcome group
Quality of life · Musculoskeletal
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Significant improvement in the QOL score was observed in both groups (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
Show in the study text Report a problemFND-3996612109
02HumanRandomized controlled trialSafety outcome
In patients with osteoporosis receiving the teriparatide sequences, no serious adverse events were reported.
In plain wordsIn patients with osteoporosis receiving the teriparatide sequences, no serious adverse events were reported.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSerious adverse events
Study
n = 358
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
No serious AEs were reported.
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
Show in the study text Report a problemFND-3996612110
03HumanRandomized controlled trialEfficacy outcome
In patients with osteoporosis, lumbar BMD increased from baseline with daily-to-twice-weekly teriparatide at 52 weeks.
In plain wordsIn patients with osteoporosis, lumbar bone density increased from baseline with daily-to-twice-weekly teriparatide at 52 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar BMD in daily-to-twice-weekly sequence
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
A significant increase in BMD from baseline was observed at the lumbar vertebrae in both groups and at the hip area in the 1/D-TPTD to 2/W-TPTD group at 52 weeks (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
Show in the study text Report a problemFND-3996612106
04HumanRandomized controlled trialEfficacy outcome
In patients with osteoporosis, lumbar BMD increased from baseline with twice-weekly-to-daily teriparatide at 52 weeks.
In plain wordsIn patients with osteoporosis, lumbar bone density increased from baseline with twice-weekly-to-daily teriparatide at 52 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar BMD in twice-weekly-to-daily sequence
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
A significant increase in BMD from baseline was observed at the lumbar vertebrae in both groups and at the hip area in the 1/D-TPTD to 2/W-TPTD group at 52 weeks (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
Show in the study text Report a problemFND-3996612107
05HumanRandomized controlled trialEfficacy outcome
In patients with osteoporosis, hip BMD increased from baseline with daily-to-twice-weekly teriparatide at 52 weeks.
In plain wordsIn patients with osteoporosis, hip bone density increased from baseline with daily-to-twice-weekly teriparatide at 52 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip BMD in daily-to-twice-weekly sequence
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
A significant increase in BMD from baseline was observed at the lumbar vertebrae in both groups and at the hip area in the 1/D-TPTD to 2/W-TPTD group at 52 weeks (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
Show in the study text Report a problemFND-3996612108

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialOther
In patients with osteoporosis, persistence was higher with daily-to-twice-weekly teriparatide than with the reverse sequence.
In plain wordsIn patients with osteoporosis, persistence was higher with daily-to-twice-weekly teriparatide than with the reverse sequence.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTreatment persistence
Study
n = 358
Comparator
Twice-weekly then daily sequence
Outcome group
Treatment adherence and retention · Musculoskeletal
Source sentences
Summary
Significantly higher persistence was observed in the 1/D-TPTD to 2/W-TPTD group (p = 0.032).
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3996612101
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialOther
In patients with osteoporosis, overall satisfaction did not differ significantly between teriparatide regimen sequences.
In plain wordsIn patients with osteoporosis, overall satisfaction did not differ significantly between teriparatide regimen sequences.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOverall satisfaction
Study
n = 358
Comparator
Other teriparatide sequence
Outcome group
Patient-reported outcomes · Musculoskeletal
Source sentences
Summary
No significant between-group differences in overall satisfaction scores or satisfaction with treatment were observed.
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3996612102
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialOther
In patients with osteoporosis, treatment satisfaction did not differ significantly between teriparatide regimen sequences.
In plain wordsIn patients with osteoporosis, treatment satisfaction did not differ significantly between teriparatide regimen sequences.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSatisfaction with treatment
Study
n = 358
Comparator
Other teriparatide sequence
Outcome group
Patient-reported outcomes · Musculoskeletal
Source sentences
Summary
No significant between-group differences in overall satisfaction scores or satisfaction with treatment were observed.
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3996612103
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialOther
In patients with osteoporosis, device utility satisfaction was higher with twice-weekly than daily teriparatide.
In plain wordsIn patients with osteoporosis, satisfaction with the injection device was higher with twice-weekly than daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseInjection device utility satisfaction
Study
n: not reported in source
Comparator
Daily teriparatide
Outcome group
Patient-reported outcomes · Musculoskeletal
Source sentences
Summary
Satisfaction with the utility of the injection device was significantly higher with the 2/W-TPTD regimen (p < 0.05);
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3996612104
10HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In patients with osteoporosis, 69.4% preferred twice-weekly teriparatide after crossover over daily teriparatide.
In plain wordsIn patients with osteoporosis, 69.4% preferred twice-weekly teriparatide over daily teriparatide after crossover.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseInjection regimen preference
Study
n: not reported in source
Comparator
Daily teriparatide
Outcome group
Patient-reported outcomes · Musculoskeletal
Measurements
Patients preferring twice-weekly regimen
69.4%
after crossover
Source sentences
Summary
Satisfaction with the utility of the injection device was significantly higher with the 2/W-TPTD regimen (p < 0.05); this regimen was preferred by 69.4% of patients after crossover (p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively.
Summary · context
After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3996612105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.